Australasian COVID-19 Trial ASCOT is a clinical trial that will generate clinical evidence about treatment for COVID-19 that can be applied during the pandemic to reduce mortality or the need for mechanical ventilation in hospitalised but not yet critically ill patients with COVID-19.
Trial Overview
1606 patients enrolled in trial
1606 patients randomised
23 sites activated
ASCOT and REMAP-CAP awarded nearly $4 million to combine platforms to test new therapeutics to treat COVID-19
September 1, 2022
ASCOT and REMAP-CAP have been awarded $3,997,914 by the Australian Government through the Medical Research Future Fund (MRFF) in a joint proposal t...
ASCOT closes the Antiviral Treatment Domain
August 15, 2022
On Thursday, 11 August 2022, the ASCOT Trial Steering Committee (TSC), with support from the Antiviral Domain-Specific Working Group (DSWG), made t...
ASCOT closes the Anticoagulation Treatment Domain
April 14, 2022
On Thursday, 7 April 2022, the ASCOT Trial Steering Committee (TSC), with support from the Anticoagulation Domain-Specific Working Group (DSWG), ma...
The ASCOT Process
01. Identify potential treatment options
02. Evaluate candidate treatments
03. Identify effective treatments & disregard ineffective treatments
04. Generate clinical evidence that can be applied during the pandemic and within the trial itself
Use left/right arrows to navigate the slideshow or swipe left/right if using a mobile device
